Table 3.

Results of interventions in mechanisms of the innate immunity in experimental models of hypertension

Experimental Model	Intervention	Results	Reference Nos.
SHR	Anti-TLR4	Hypertension ameliorated (MAP: not treated = 160 mmHg; treated = 140 mmHg), reduced vascular contractility	20
	Brain (PVN) blockade of TLR4	Hypertension ameliorated (MAP: not treated = 170 mmHg; treated = 142 mmHg), cardiac hypertrophy ameliorated, reduction of HMGB1	46
SPSHR	IL-1β administration	Increase in stroke incidence, blood pressure not modified	35
Dahl SS	P2X7 receptor antagonist	Amelioration of SS hypertension, (SBP: not treated = 195 mmHg; treated = 165 mmHg), reduction of inflammation and albuminuria	120
ANG II	Anti-TLR4 antibody	Reduced inflammation in VSMC	119
DOCA-salt	C5a receptor antagonist	Reduction of heart inflammation and fibrosis, hypertension unchanged	116
	ASC−/−	Amelioration of hypertension (SBP: WT = 155 mmHg; ASC −/− = 140 mmHg), reduced inflammation	140
	Inhibition of inflammasome (MCC960)	Amelioration of hypertension (SBP: NT = 160 mmHg; Treated = 140 mmHg), reduced Inflammation	140
l-NAME	TLR4−/−	Amelioration of hypertension (MAP: WT = 125 mmHg; TLR4−/− = 100 mmHg), reduction in arterial contractility, reduced inflammation	247
Unilateral uretheral obstruction	C3−/−	Amelioration of hypertension (SBP: WT = 120 mmHg; C3−/− = 105 mmHg), reduction in intrarenal ANG II, reduction in EMT	329

The majority experimental interventions on elements of innate immunity ameliorate hypertension. TLR, Toll-like receptor, PVN, paraventricular nuclei; ASC, adapter protein, apoptosis-associated speck-like protein containing a caspase activation and recruitment domain; EMT, epithelial mesenchymal transition; SS, salt sensitive; SBP, systolic blood pressure; MAP, mean arterial pressure; WT, wild type receiving the corresponding hypertensive treatment.